Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

Peer Review reports

Original Submission
17 Apr 2018	Submitted	Original manuscript
27 May 2018	Reviewed	Reviewer Report - Shailesh Advani
17 Jun 2018	Reviewed	Reviewer Report - Noemia Afonso
11 Jul 2018	Author responded	Author comments - Wenxiong Zhang
Resubmission - Version 2
11 Jul 2018	Submitted	Manuscript version 2
17 Jul 2018	Author responded	Author comments - Wenxiong Zhang
Resubmission - Version 3
17 Jul 2018	Submitted	Manuscript version 3
Publishing
22 Jul 2018	Editorially accepted
2 Aug 2018	Article published	10.1186/s12885-018-4685-y

Back to article page